Avextra AG has announced the closing of a capital raise worth EU 17 Million (via a convertible loan note) supported by its current investors, entire management team and additional investors from across Europe.

"We are very proud of the confidence investors have shown us. We will continue building on our success to make Avextra a leader in compound medicines in Germany and selected European geographies while also accelerating our unique path towards IP and Rx products,” stated Bernhard Babel, co-CEO of Avextra AG.

About The Company: Avextra AG is one of Europe’s leading vertically integrated suppliers of high-quality …

Full story available on Benzinga.com